PMID- 34196677
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20230920
IS  - 2473-9537 (Electronic)
IS  - 2473-9529 (Print)
IS  - 2473-9529 (Linking)
VI  - 5
IP  - 13
DP  - 2021 Jul 13
TI  - Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory 
      large B-cell lymphomas.
PG  - 2707-2716
LID - 10.1182/bloodadvances.2020004155 [doi]
AB  - The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved 
      in combination with bendamustine and rituximab (pola-BR) for patients with 
      refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the 
      efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 
      patients with LBCL who were treated in 26 German centers under the national 
      compassionate use program. Fifty-four patients received pola as a salvage 
      treatment and 51 patients were treated with pola with the intention to bridge to 
      chimeric antigen receptor (CAR) T-cell therapy (n = 41) or allogeneic 
      hematopoietic cell transplantation (n = 10). Notably, patients in the salvage and 
      bridging cohort had received a median of 3 prior treatment lines. In the salvage 
      cohort, the best overall response rate was 48.1%. The 6-month progression-free 
      survival and overall survival (OS) was 27.7% and 49.6%, respectively. In the 
      bridging cohort, 51.2% of patients could be successfully bridged with pola to the 
      intended CAR T-cell therapy. The combination of pola bridging and successful CAR 
      T-cell therapy resulted in a 6-month OS of 77.9% calculated from pola initiation. 
      Pola vedotin-rituximab without a chemotherapy backbone demonstrated encouraging 
      overall response rates up to 40%, highlighting both an appropriate alternative 
      for patients unsuitable for chemotherapy and a new treatment option for bridging 
      before leukapheresis in patients intended for CAR T-cell therapy. Furthermore, 7 
      of 12 patients with previous failure of CAR T-cell therapy responded to a 
      pola-containing regimen. These findings suggest that pola may serve as effective 
      salvage and bridging treatment of r/r LBCL patients.
CI  - (c) 2021 by The American Society of Hematology.
FAU - Liebers, Nora
AU  - Liebers N
AD  - Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
AD  - National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.
FAU - Duell, Johannes
AU  - Duell J
AD  - Department of Internal Medicine II, Wurzburg University Hospital, University of 
      Wurzburg, Wurzburg, Germany.
FAU - Fitzgerald, Donnacha
AU  - Fitzgerald D
AUID- ORCID: 0000-0003-4927-7484
AD  - Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
AD  - European Molecular Biology Laboratory, Heidelberg, Germany.
FAU - Kerkhoff, Andrea
AU  - Kerkhoff A
AD  - Department of Medicine A, University Hospital Munster, Munster, Germany.
FAU - Noerenberg, Daniel
AU  - Noerenberg D
AD  - Department of Hematology, Oncology and Tumor Immunology (Campus 
      Virchow-Klinikum), Charite University Medicine, Berlin, Germany.
FAU - Kaebisch, Eva
AU  - Kaebisch E
AUID- ORCID: 0000-0001-7752-4126
AD  - Department of Hematology, Oncology and Tumor Immunology (Campus 
      Virchow-Klinikum), Charite University Medicine, Berlin, Germany.
FAU - Acker, Fabian
AU  - Acker F
AUID- ORCID: 0000-0002-6207-0237
AD  - Department of Medicine 2, Hematology and Oncology, University Hospital Frankfurt, 
      Frankfurt, Germany.
FAU - Fuhrmann, Stephan
AU  - Fuhrmann S
AUID- ORCID: 0000-0002-7785-2565
AD  - Department of Hematology, HELIOS Klinikum Berlin-Buch, Berlin, Germany.
FAU - Leng, Corinna
AU  - Leng C
AD  - Department of Hematology, Oncology, and Tumor Immunology (Campus Benjamin 
      Franklin), Charite University Medicine, Berlin, Germany.
FAU - Welslau, Manfred
AU  - Welslau M
AD  - MVZ am Klinikum Aschaffenburg, Onkologie und Hamatologie, Aschaffenburg, Germany.
FAU - Chemnitz, Jens
AU  - Chemnitz J
AD  - Gemeinschaftsklinikum Mittelrhein GmbH, Koblenz, Germany.
FAU - Middeke, Jan-Moritz
AU  - Middeke JM
AD  - University Hospital Dresden, Dresden, Germany.
FAU - Weber, Thomas
AU  - Weber T
AUID- ORCID: 0000-0002-8724-9348
AD  - Department of Medicine IV, Hematology and Oncology, University of Halle, Halle, 
      Germany.
FAU - Holtick, Udo
AU  - Holtick U
AD  - Department I of Internal Medicine, Medical Faculty and University Hospital, 
      Cologne, University of Cologne, Cologne, Germany.
FAU - Trappe, Ralf
AU  - Trappe R
AD  - Department of Hematology and Oncology, DIAKO Ev. Diakonie-Krankenhaus Bremen, 
      Bremen, Germany.
FAU - Pfannes, Roald
AU  - Pfannes R
AD  - Department of Medicine I, Stadtisches Klinikum Dessau, Dessau, Germany.
FAU - Liersch, Ruediger
AU  - Liersch R
AD  - Praxis Medical Center, Gemeinschaftspraxis fur Hamatologie und Onkologie Munster, 
      Munster, Germany.
FAU - Spoer, Christian
AU  - Spoer C
AD  - MVZ am EVK Dusseldorf, Internistische Onkologie und Hamatologie, Dusseldorf, 
      Germany.
FAU - Fuxius, Stefan
AU  - Fuxius S
AD  - Onkologische Schwerpunktpraxis Heidelberg, Heidelberg, Germany.
FAU - Gebauer, Niklas
AU  - Gebauer N
AD  - Department of Haematology and Oncology, University Hospital of 
      Schleswig-Holstein, Campus Lubeck, Germany.
FAU - Caille, Leandra
AU  - Caille L
AD  - Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
FAU - Geer, Thomas
AU  - Geer T
AD  - Diakonie Klinikum Schwabisch-Hall, Innere Medizin III, Schwabisch Hall, Germany.
FAU - Koenecke, Christian
AU  - Koenecke C
AUID- ORCID: 0000-0001-7025-1735
AD  - Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, 
      Hannover Medical School, Hannover, Germany.
FAU - Keller, Ulrich
AU  - Keller U
AUID- ORCID: 0000-0002-8485-1958
AD  - Department of Hematology, Oncology, and Tumor Immunology (Campus Benjamin 
      Franklin), Charite University Medicine, Berlin, Germany.
FAU - Claus, Rainer
AU  - Claus R
AUID- ORCID: 0000-0003-2617-8766
AD  - Hematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, 
      Germany.
FAU - Mougiakakos, Dimitrios
AU  - Mougiakakos D
AD  - Department of Internal Medicine 5, Hematology and Clinical Oncology, 
      Friedrich-Alexander University (FAU) of Erlangen-Nuremberg, Erlangen, Germany.
FAU - Mayer, Stephanie
AU  - Mayer S
AD  - Department of Internal Medicine III, University Hospital of Regensburg, 
      Regensburg, Germany.
FAU - Huettmann, Andreas
AU  - Huettmann A
AUID- ORCID: 0000-0003-2230-3873
AD  - Department of Hematology, University Hospital of Essen, Essen, Germany.
FAU - Pott, Christiane
AU  - Pott C
AD  - Second Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, 
      Germany.
FAU - Trummer, Arne
AU  - Trummer A
AD  - Department of Hematology and Oncology, Klinikum Braunschweig, Braunschweig, 
      Germany.
FAU - Wulf, Gerald
AU  - Wulf G
AD  - Clinic for Hematology and Medical Oncology, University Medicine Gottingen, 
      Germany; and.
FAU - Brunnberg, Uta
AU  - Brunnberg U
AD  - Department of Medicine 2, Hematology and Oncology, University Hospital Frankfurt, 
      Frankfurt, Germany.
FAU - Bullinger, Lars
AU  - Bullinger L
AD  - Department of Hematology, Oncology and Tumor Immunology (Campus 
      Virchow-Klinikum), Charite University Medicine, Berlin, Germany.
FAU - Hess, Georg
AU  - Hess G
AD  - Department of Hematology, Oncology and Pneumology, Johannes Gutenberg-University, 
      Mainz, Germany.
FAU - Mueller-Tidow, Carsten
AU  - Mueller-Tidow C
AD  - Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
AD  - National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.
FAU - Glass, Bertram
AU  - Glass B
AD  - Department of Hematology, HELIOS Klinikum Berlin-Buch, Berlin, Germany.
FAU - Lenz, Georg
AU  - Lenz G
AD  - Department of Medicine A, University Hospital Munster, Munster, Germany.
FAU - Dreger, Peter
AU  - Dreger P
AD  - Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
FAU - Dietrich, Sascha
AU  - Dietrich S
AD  - Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
AD  - National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.
AD  - European Molecular Biology Laboratory, Heidelberg, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Blood Adv
JT  - Blood advances
JID - 101698425
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Immunoconjugates)
RN  - KG6VO684Z6 (polatuzumab vedotin)
SB  - IM
MH  - Antibodies, Monoclonal
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Humans
MH  - *Immunoconjugates
MH  - Retrospective Studies
MH  - *Salvage Therapy
PMC - PMC8288676
EDAT- 2021/07/02 06:00
MHDA- 2021/07/13 06:00
PMCR- 2021/07/01
CRDT- 2021/07/01 12:19
PHST- 2020/12/30 00:00 [received]
PHST- 2021/03/20 00:00 [accepted]
PHST- 2021/07/01 12:19 [entrez]
PHST- 2021/07/02 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
PHST- 2021/07/01 00:00 [pmc-release]
AID - S2473-9529(21)00350-5 [pii]
AID - 2021/ADV2020004155 [pii]
AID - 10.1182/bloodadvances.2020004155 [doi]
PST - ppublish
SO  - Blood Adv. 2021 Jul 13;5(13):2707-2716. doi: 10.1182/bloodadvances.2020004155.